市場調査レポート
商品コード
1123140
DNAワクチンの世界市場:予測(2022年~2028年)Global DNA Vaccine Market Research and Forecast, 2022-2028 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
DNAワクチンの世界市場:予測(2022年~2028年) |
出版日: 2022年07月23日
発行: Orion Market Research
ページ情報: 英文 110 Pages
納期: 2~3営業日
|
世界のDNAワクチンの市場規模は、予測期間(2021年~2027年)中に約7.6%のCAGRで拡大すると予測されています。市場成長の要因としては、様々な抗生物質耐性病原体の増加や感染症患者の増加により、長期間にわたって免疫を獲得できる、低コストで有効なワクチンのニーズが高まっていることが挙げられます。
当レポートでは、世界のDNAワクチン市場について調査し、市場の概要とともに、タイプ別、技術別、用途別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。Global DNA Vaccine Market Size, Share & Trends Analysis Report By Type (Animal DNA Vaccine and Human DNA Vaccine), By Technology (Plasmid DNA Vaccines Technology and Plasmid DNA Delivery Technology), By Application (Oncology, Infectious Diseases, and Others) Forecast, 2021-2027
The global DNA vaccines market is growing at a considerable CAGR of around 7.6% during the forecast period (2021-2027). The factors that drive the growth of the market include the increasing number of various antibiotics resistant pathogens and the increasing population with infectious diseases that have created the need for low-cost and efficacious vaccines that would deliver immunity for a long period. The DNA vaccines are also effective against infectious diseases in animals and have successfully eliminated key animal pathogens. DNA vaccines come with numerous advantages such as the low risk of infection as compared to conventional vaccines, easy transference, and constancy at room temperature. Additionally, rapid development in the field of molecular biology, immunology, and DNA synthesis contributing to the growth of the market. Along with that, the inefficient drug therapies and rising microbial resistance to existing 'antimicrobials and antibiotics' treatments providing ample opportunity to increase the DNA vaccine market during the forecast period.
Impact of COVID-19 on the Global DNA Vaccines Market
The COVID-19 pandemic has a positive impact on the global DNA vaccines market since December 2019. The market is increasing due to the development of vaccines as the globe deals to find a cure for the disease. The major market players are focusing on the ongoing clinical trials of nucleic acid vaccines against COVID-19 with the use of DNA technology. For instance, In April 2020. INOVIO Pharmaceuticals, the US-based biotech company announced that the company is in phase I clinical trial to protect against COVID-19. The characteristic of the vaccine is DNA plasmid encoding S protein delivered by electroporation. Additionally, In June 2021, The company expands its partnership with Advaccine Biopharmaceuticals Suzhou Co., Ltd. to conduct a global Phase 2/3 efficiency trial of the COVID-19 DNA vaccine.
Segmental Outlook
The market is segmented based on type, technology, application. Based on type, the market is segmented into animal DNA vaccine and human DNA vaccine. Based on technology, the market is segmented into plasmid DNA vaccines technology and plasmid DNA delivery technology. On the basis of application, the market is segmented into oncology, infectious diseases, and others.
Global DNA Vaccines Market Share by Type, 2020 (%)
Global DNA Vaccines Market Share by Type
The Animal Vaccine segment is projected to grow significantly in the global DNA Vaccine market
Among types, The animal DNA vaccine segment is estimated to grow significantly in the global animal vaccine market during the forecast period. The segment is increasing due to the increasing availability of DNA Vaccines for animal diseases that includes West Nile Innovator (Horse), Apex-IHN (Salmon fish), canine melanoma vaccine (DOG), and Life tide-SW5 (Swine and other food animals). Hence, the rising prevalence of these diseases creates an opportunity for animal DNA vaccine manufacturers. Additionally, the DNA vaccine is more effective and less expensive as compared to other vaccines. DNA vaccines are suitable for mass vaccination, and. DNA vaccines have been prospective solutions for poultry diseases. DNA vaccines can be used for immediate jabs in contradiction of multiple pathogens and are comparatively easy to design and inexpensive to manufacture and store.
Regional Outlooks
The global DNA vaccines market is analyzed based on the geographical regions that are contributing significantly towards the growth of the market. Based on the geography, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America developed as a profitable market for DNA vaccines market. The market is increasing in North America due to the initiatives by the regional government to immunize citizens, along with the prevalence of the aids of genetic vaccines targeted towards animals. For instance, In May 2021, GC Pharma announced that the US Food and Drug Administration (FDA) accepted the company's Biologics License Application (BLA) for 'GC5107 (Immune Globulin Intravenous (Human),10% Liquid)' anticipated for the treatment of Primary Humoral Immunodeficiency (PI), which is a type of congenital genetic disorders that causes an individual to have a lacking or absent immune system.
Global DNA Vaccines Market, by Region 2021-2027
Global DNA Vaccines Market, by Region
Asia-Pacific will Have Considerable Growth in the Global DNA Vaccines market
Asia-Pacific is estimated to have considerable growth in the global DNA vaccine market during the forecast period. The market is increasing in this region due to the rising government initiatives, and increasing prevalence of people regarding the benefits of vaccination against Human papillomavirus (HPV) and Hepatitis B. are some factors that drive the growth of the market in the Asia-Pacific.
Market Player Outlook
Key players of the global DNA vaccines market include Pfizer Inc., Merck & Co., Inc., Sanofi S.A., Serum Institute of India Pvt. Ltd., INOVIO Pharmaceuticals., General Electric Co., GlaxoSmithKline plc., Hoffmann-La Roche Ltd, Bharat Biotech International Ltd., GC Pharma corp., and others. To sustain a significant position in the market, these players adopt different marketing strategies such as product launches. For instance, in 2018, Astellas Pharma Inc entered into a global partnership worldwide (excluding China), with Juventas Therapeutics, the agreement was for option, and license agreement for Juventas' lead product candidate, JVS-100. JVS-100. It is a non-viral gene therapy that expresses stromal cell-derived factor-1 (SDF-1).
The Report Covers
Market value data analysis of 2020 and forecast to 2027.
Annualized market revenues ($ million) for each market segment.
Country-wise analysis of major geographical regions.
Key companies operating in the global DNA vaccines market based on the availability of data, information related to new product launches, and relevant news is also available in the report.
Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
Analysis of market entry and market expansion strategies.
Competitive strategies by identifying 'who-stands-where in the market